A new multicenter trial focuses on
providing precision treatments for rare cancers based on genetics, not tumor site.
Not exact matches
«Once the ovarian cancer becomes drug resistant we can not cure it,» says Rodriguez a gynecologic oncologist who
provides treatment to ovarian cancer patients and is director of the
precision medicine initiative at Rutgers Cancer Institute of New Jersey.
This new commitment to the
precision medicine initiative will
provide additional opportunities over the next three years for physicians to analyze the genomic profiles of pediatric patients to better understand their cancers and help improve
treatment options.
Therefore, Liquid Biopsy
provides the ideal scheme to personalize the
treatment in
precision medicine.
Despite the rapid change of the increasingly effective technology, we work hard to stay at the cutting edge of what is available in order to
provide the most effective
treatment, and the highly experienced team employs these tools with great skill and
precision.